ArticleCJC open2026
Antiplatelet Therapy Strategies in Patients with High Bleeding Risk Treated with Complex Percutaneous Coronary Intervention: A Descriptive Study.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Following acute coronary syndrome (ACS) treated by percutaneous coronary intervention (PCI), guideline-directed dual antiplatelet therapy (DAPT) typically consists of 12 months of aspirin plus a P2Y Methods: Patients undergoing PCI for ACS were randomly sampled from those hospitalized at the Montreal Heart Institute between May 1, 2024 and April 30, 2025. Data were extracted from electronic health records. HBR was assessed using the Results: Of the 309 participants sampled, 35% were identified as being at HBR, 43% underwent complex PCI, and 17.5% (95% confidence interval, 13.3%-21.7%) met both HBR and complex PCI criteria. De-escalation strategies were infrequently prescribed across risk groups, even among patients at HBR without complex PCI. Among those not receiving long-term anticoagulation, only 4.2% received a de-escalation strategy. Conclusions: Nearly 1 in 6 patients undergoing PCI for ACS met both HBR and complex PCI criteria. In this setting, clinicians appeared to favour standard-duration clopidogrel-based DAPT rather than de-escalation approaches. These findings underscore the need for practical guidance to support individualized antiplatelet decision-making in patients with competing bleeding and ischemic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.